Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects

AIDS

Volumn 14, Issue 1, 2000, Pages 51-57

  Purnell, Jonathan Q ^a   Zambon, Alberto ^a   Knopp, Robert H ^a   Pizzuti, David J ^b   Achari, Ramanuj ^b   Leonard, John M ^b   Locke, Charles ^b   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Apolipoproteins; Hepatic lipase; Lipids; Lipoprotein lipase; Ritonavir

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FEMALE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

ADULT; APOLIPOPROTEINS B; BODY WEIGHT; CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; PLACEBOS; RITONAVIR; TRIGLYCERIDES;

EID: 0033963686     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00006     Document Type: Article

References (37)

1. 1. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pearson J RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
2. 2. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045 1052.
3. 3. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endorinol Metab 1993, 76:1423-1427.
4. 4. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1291.
5. 5. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmocokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533.
6. 6. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection, tancer 1998, 351:867-870.
7. 7. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
8. 8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
9. 9. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
10. 10. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD. The visceral adiposity syndrome in Japanese-American men. Obesity Res 1994, 2:364-371.
11. 11. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996, 19:629-637.
12. 12. Lipid and lipoprotein analysis. In: Manual of laboratory operations, lipid research clinics program. Bethesda, MD: National Institutes of Health; 1974. pp. 75-628.
13. 13. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation of high-density lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
14. 14. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 1986, 129:101-123.
15. 15. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994, 40:586-592.
16. 16. Marcovina SM, Albers JJ, Gabel B, Koshinsky ML, Guar VP. Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a). Clin Chem 1995, 41:246-255.
17. 17. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 1989, 9:319-325.
18. 18. Iverius P-H, Brunzell JD. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma. Am J Physiol 1985, 249:E107-E114.
19. 19. Shirai K, Barnhart RL, Jackson RL. Hydrolysis of human plasma high density lipoprotein 2-phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun 1981, 100: 591-599.
20. 20. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993, 13:147-153.
21. 21. Despres J-P, Ferland M, Moorjani S, et al. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 1989, 9:485-492.
22. 22. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875-881.
23. 23. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276: 882-888.
24. 24. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999, 99:1959-1964.
25. 25. Applebaum DM, Goldberg AP, Pykalisto OJ, Brunzell JD, Hazzard WR. Effect of estrogen on post-heparin lipolytic activity: selective decline in hepatic triglyceride lipase. J Clin Invest 1977, 59:601-608.
26. 26. Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982, 54:1113-1117.
27. 27. Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T. Reversible modification of human plasma low density lipoprotcins toward triglyceride-rich precursors. J Biol Chem 1982, 257:6509-6517.
28. 28. Knopp RH, Zhu X-D, Lau J, Waiden C. Sex hormones and lipid interactions: implications for cardiovascular disease in women. The Endocrinologist 1994, 4:286-301.
29. 29. Campos H, Walsh BW, Judge H, Sacks FM. Effect of estrogen on VLDL and LDL metabolism in postmenopausal women. J Clin Endocrinol Metab 1997, 82:3955-3963.
30. 30. Knopp RH, Zhu X. Multiple beneficial effects of estrogen on lipoprotein metabolism. J Clin Endocrinol Metab 1997, 82:3952-3954.
31. 31. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983, 24:147-155.
32. 32. Carr A, Samaras K, Chisholm DJ. Hypothesis: pathogensis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 351: 1881-1883.
33. 33. Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein (a) as risk factors for coronary artery disease. Med Clin North Am 1994, 78: 99-115.
34. 34. Fauchter C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J. Elevated Lp(a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993, 22:808-813.
35. 35. Segarra A, Chacon P, Martin M, et al. Serum lipoprotein (a) levels in patients with chronic renal failure - evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1994, 69: 9-13.
36. 36. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein (a). Clin Chem 1993, 39:2466-2469.
37. 37. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med 1996, 156:500-504.